Replies to post #179807 on Biotech Values

[DewDiligence]

NeuClone, Serum Institute of India ink global FoB collaboration:

http://lifescientist.com.au/content/biotechnology/news/neuclone-signs-biosimilar-deal-with-serum-institute-972901099

Sydney-based biotech NeuClone has signed a…licensing agreement and joint development partnership with The Serum Institute of India covering the manufacturing of 10 biosimilar drugs.

Under the agreement, NeuClone will use its NeuMAX cell line development platform to manufacture and supply 10 biosimilar monoclonal antibody drugs. The Serum Institute, the world’s largest vaccine producer, will provide its biologics manufacturing capability

The drugs will have targets including cancer and autoimmune disorders, and each will address markets worth hundreds of millions to billions of dollars…

…NeuClone will retain the licence to the biosimilars for the markets of the US, Europe, Canada, Australia, Taiwan, Japan and South Korea. The company said it will seek partnerships with large pharmaceutical and generics companies in these markets. The Serum Institute will meanwhile receive an exclusive worldwide licence for marketing and sales of the drug in the rest of the world.

…The partners plan to develop multiple biosimilars simultaneously and eventually take all 10 products through clinical trials and onto the market.

[DewDiligence]

Announced FoB Collaborations

[Added entry for NeuClone–Serum Institute of India.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.

 
                     Date   Targets   Geography     iHub References 
 NeuClone-Serum Inst 7/14   10 mAbs   global        #msg-104136710 
 Liomont-Oncobiolgcs 6/14   2 mAbs    Mexico        #msg-103754486 
 PlantForm-PhrmaPrxs 6/14   Avastin+  Brazil        #msg-103576633 
 Lupin-Yoshindo      4/14   Enbrel+   Japan         #msg-101018361 
 BAX-Coherus         9/13   Enbrel    ex-US         #msg-91645674 
 Oncobiolgcs-Huahai  5/13   #         global        #msg-87734336,#msg-87744882 
 Strides-Pfenex      4/13   Betaseron global        #msg-87014470 
 MRK-Samsng/BIIB     2/13   @         Europe+       #msg-84781042,#msg-69629103,#msg-95065880 
 Catalent-UMN       12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY      6/12   oncology  global        #msg-76359649 
 Daiichi-Coherus     5/12   *         Asia          #msg-75397629 
 Fujifilm-Kyowa      3/12   Humira    unspecified   #msg-73800486 
 ACT-Bioton          2/12   insulin   US & Europe   #msg-74987123 
 ACT-AMGN           12/11   †         global        #msg-70097496,#msg-84340328 
 BAX-MNTA           12/11   ‡         global        #msg-70212854,#msg-70258421 
 HSP-Celltrion      10/09   z         global        #msg-84519981,#msg-77816122 
 MYL-Biocon          6/09   x         global        #msg-72421544,#msg-84561737 
 Procognia-UTR       n/a    Humira    unspecified   #msg-84340976 

*Enbrel and Rituxan.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis developing Remicade and Enbrel FoB’s in Europe (#msg-95065880); Rituxan program terminated (#msg-80622249).

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.

z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.